96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA  | Zendy

Nathan Clumeck | Zendy; A. Rieger | Zendy; Dénes Bánhegyi | Zendy; Wolfgang Schmidt | Zendy; A.D. Hill | Zendy; Yvon van Delft | Zendy; Christiane Moecklinghoff | Zendy; José Ramón Arribas | Zendy

Open Access

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline

Author(s) -

Nathan Clumeck,

A. Rieger,

Dénes Bánhegyi,

Wolfgang Schmidt,

A.D. Hill,

Yvon van Delft,

Christiane Moecklinghoff,

José Ramón Arribas

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr199

Subject(s) - darunavir , ritonavir , medicine , discontinuation , adverse effect , confidence interval , randomized controlled trial , gastroenterology , viral load , human immunodeficiency virus (hiv) , virology , antiretroviral therapy

In virologically suppressed patients, switching to darunavir/ritonavir monotherapy could avoid resistance and adverse events from continuing nucleoside analogues.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research